BioMerieux (FRA:EYWN) Total Operating Expense: €1,614 Mil (TTM As of Dec. 2025)


FRA:EYWN BioMerieux SA FRA:EYWN
66 GF Score
Price €68.35
GF Value €109.06
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Total Operating Expense?

BioMerieux FRA:EYWN -1.80% 66 Total Operating Expense is €1,614 Mil as of Dec. 2025. GuruFocus rates FRA:EYWN with a GF Score™ of 66/100 and a GF Value™ of €109.06 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMerieux's Total Operating Expense for the six months ended in Dec. 2025 was €803 Mil. BioMerieux's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €1,614 Mil.

BioMerieux Total Operating Expense Related Terms

BioMerieux Total Operating Expense Historical Data

* Premium members only.

The historical data trend for BioMerieux's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMerieux Total Operating Expense Chart

BioMerieux Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,156.80 1,382.90 1,488.30 1,577.40 1,614.10

BioMerieux Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 760.10 774.50 802.90 811.40 802.70
FRA:EYWN
66GF Score
BioMerieux SA FRA:EYWN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMerieux Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1,614 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €1,614 Mil mean?
BioMerieux (FRA:EYWN) has a Total Operating Expense of €1,614 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on BioMerieux and its competitors.
Is BioMerieux's Total Operating Expense too high?
BioMerieux's current Total Operating Expense is €1,614 Mil. Overall, BioMerieux has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's Total Operating Expense compare to TMO and DHR?
BioMerieux's Total Operating Expense of €1,614 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Diagnostics & Research company?
A good Total Operating Expense depends on the Medical Diagnostics & Research industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on BioMerieux and its competitors. BioMerieux's current Total Operating Expense is €1,614 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (FRA:EYWN) is currently considered Significantly Undervalued. The stock's GF Value™ is €109.06, compared to a current price of €68.35 — trading 37.3% below its estimated fair value. The current Total Operating Expense is €1,614 Mil. BioMerieux's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For BioMerieux (FRA:EYWN), the current Total Operating Expense is €1,614 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMerieux (FRA:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €68.35 is trading 37.3% below its estimated GF Value™ of €109.06. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for FRA:EYWN:

  • Total Operating Expense: €1,614 Mil
  • GF Value™: €109.06 vs. price of €68.35 (37.3% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the FRA:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
66GF Score

Get the complete analysis for FRA:EYWN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.35
Price
€109.06
GF Value